|
|
|
|
|
Paramethadione
drug data and news
Paramethadione drug data, resources, and news articles (when available). Onconews.org provides news on cancer research. This section, which includes profiles on medicines that may or not be cancer-related is in beta form. If things run smoothly we will be releasing a new format late in the summer of 2006.
|
| Generic name | Paramethadione | ||
| Brand Names/Synonyms | A 348; HSDB 3245; Isoethadione; PARAMETHADIONE; Paradione; Parametadiona [Inn-Spanish]; Parametadione; Parametadione [Dcit]; Paramethadione; Paramethadione [Ban:Inn]; Paramethadionum [Inn-Latin] | ||
| Indication | Used to control certain types of seizures in the treatment of epilepsy | ||
| Sponsored links | Description | Not Available | |
| Pharmacology | Paramethadione and trimethadione are anticonvulsants indicated in the control of absence (petit mal) seizures that are refractory to treatment with other medications. Dione anticonvulsants are used in the treatment of epilepsy. They act on the central nervous system (CNS) to reduce the number of seizures. | ||
| Mechanism Of Action | Dione anticonvulsants reduce T-type calcium currents in thalamic neurons, including thalamic relay neurons. This raises the threshold for repetitive activity in the thalamus, and inhibits corticothalamic transmission. Thus, the abnormal thalamocortical rhythmicity, which is thought to underlie the 3-Hz spike-and-wave discharge seen on electroencephalogram(EEG) with absence seizures, is dampened. | ||
| Paramethadione News (When available) |
| ||
| Dosage Forms | TABLETS | ||
| Drug_Category | Anticonvulsants; ATC:N03AC01 | ||
| Absorption | Not Available | ||
| Interactions |
Interactions for Paramethadione: Not compatible with CNS depressants or trycyclic antidepressants | ||
| Toxicity | Overdoses lead to clumsiness, dizziness, drowsiness, nausea and vision problems | ||
| Organisms Affected | Humans and other mammals | ||
| Chemical IUPAC Name | 5-ethyl-3,5-dimethyl-oxazolidine-2,4-dione | ||
| Chemical Formula | C7H11NO3 | ||
| Molecular Weight | 157.167 g/mol | ||
| Smiles String | CCC1(C(=O)N(C(=O)O1)C)C | ||
| Melting Point | 101.5 oC (BP) | ||
| Water Solubility | 8.4 mg/mL | ||
| State | Liquid | ||
| LogP/Hphobicity | 0.763 | ||
| Isoelectric Point | Not Available | ||
| Biotransformation | Primarily hepatic, 5-ethyl-5-methyl-2,4-oxazolidinedione is the major metabolite | ||
| Half Life | >48 hours | ||
| Protein Binding [%] | Not Available | ||
| RxList Link | Not Available>RXlist | ||
| Sponsored links | |||
| Drug Reference | http://www.drugs.com/cons/Paramethadione.html | ||
| Drug Type | Approved Drug | ||
| Accession No | APRD00236 | ||
| CAS Registry Number | 115-67-3 | ||
| KEGG Compound ID | C07411 | ||
| PubChem ID | SID:9615 | ||
| PharmGKB ID | PA450792 | ||
| SwissProt ID | Not Available | ||
| GenBank ID | Not Available | ||
| Drug ID Number [DIN] | Not Available |
|
Home | About | Cancers | Treatment | Medications Copyright onconews.org 2005. All Rights Reserved. |